Skip to Main Content

Paper Details

Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol
6
2022
MOST, MOST-S26, MOST-S26-DorT, anxiety, fatigue, ovarian cancer, patient, patients, platinum, sore hands and feet
Author NameAffiliation
Anna DeFazioThe Westmead Institute for Medical Research, The University of Sydney, Westmead Hospital
Anna DeFazioThe Westmead Institute for Medical Research, The University of Sydney, Westmead Hospital
  • 1 - 2

Datasets

Release 1.2